Plasminogen activator inhibitor type-1 (PAI-1) polymorphism 4G/5G is associated with prostate cancer among men with a positive family history

Prostate

Volumn 67, Issue 2, 2007, Pages 172-177

  Jorgenson, Eric ^a   Deitcher, Steven R ^b   Cicek, Mine ^d   Liu, Xin ^a   Plummer, Sarah ^c   Casey, Graham ^c   Witte, John S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Nuvelo Inc   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d Mayo Clinic   (United States)

Author keywords

Association; Family history; PAI 1; Plasminogen; Prostate cancer

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CANCER GROWTH; CANCER RISK; CARCINOGENESIS; CASE CONTROL STUDY; CONTROLLED STUDY; FAMILY HISTORY; GENE DELETION; GENE INSERTION; GENE OVEREXPRESSION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; ONSET AGE; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; UNITED STATES;

AGE OF ONSET; FAMILY HEALTH; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MICHIGAN; MIDDLE AGED; OHIO; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMORPHISM, GENETIC; PROSTATIC NEOPLASMS; QUESTIONNAIRES; RISK FACTORS; SIBLINGS;

EID: 33846582827     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20512     Document Type: Article

References (21)

1. Chorostowska-Wynimko J, Skrzypczak-Jankun E, Jankun J. Plasminogen activator inhibitor type-1: Its structure, biological activity and role in tumorigenesis (Review). Int J Mol Med 2004;13(6):759-766.
2. Yamamoto K, Saito H. A pathological role of increased expression of plasminogen activator inhibitor-1 in human or animal disorders. Int J Hematol 1998;68(4):371-385.
3. Gershtein ES, Kushlinskii NE. Urokinase and tissue plasminogen activators and their inhibitor PAI-1 in human tumors. Bull Exp Biol Med 2001;131(1):67-72.
4. Swiercz R, Wolfe JD, Zaher A, Jankun J. Expression of the plasminogen activation system in kidney cancer correlates with its aggressive phenotype. Clin Cancer Res 1998;4(4):869-877.
5. Kaneko T, Konno H, Baba M, Tanaka T, Nakamura S. Urokinase-type plasminogen activator expression correlates with tumor angiogenesis and poor outcome in gastric cancer. Cancer Sci 2003;94(1):43-49.
6. Stefansson S, Petitclerc E, Wong MK, McMahon GA, Brooks PC, Lawrence DA. Inhibition of angiogenesis in vivo by plasminogen activator inhibitor-1. J Biol Chem 2001;276(11):8135-8141.
7. Swiercz R, Keck RW, Skrzypczak-Jankun E, Selman SH, Jankun J. Recombinant PAI-1 inhibits angiogenesis and reduces size of LNCaP prostate cancer xenografts in SCID mice. Oncol Rep 2001;8(3):463-470.
8. Soff GA, Sanderowitz J, Gately S, Verrusio E, Weiss I, Brem S, et al. Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis, and metastasis to lung and liver in an athymic mouse model. J Clin Invest 1995;96(6):2593-2600.
9. Margaglione M, Grandone E, Vecchione G, Cappucci G, Giuliani N, Colaizzo D, Celentano E, Panico S, Di Minno G. Plasminogen activator inhibitor-1 (PAI-1) antigen plasma levels in subjects attending a metabolic ward: Relation to polymorphisms of PAI-1 and angiontensin converting enzyme (ACE) genes. Arterioscler Thromb Vasc Biol 1997; 17(10):2082-2087.
10. Rybicki BA, Conti DV, Moreira A, Cicek M, Casey G, Witte JS. DNA repair gene XRCC1 and XPD polymorphisms and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2004;13(1):23-29.
11. Lubin JH, Hartge P. Excluding controls: Misapplications in case-control studies. Am J Epidemiol 1984;120(5):791-793.
12. Poole C. Controls who experienced hypothetical causal intermediates should not be excluded from case-control studies. Am J Epidemiol 1999;150(6):547-551.
13. Witte JS, Gauderman WJ, Thomas DC. Asymptotic bias and efficiency in case-control studies of candidate genes and gene-environment interactions: Basic family designs. Am J Epidemiol 1999;149(8):693-705.
14. Slattery ML, Edwards SL, Samowitz W, Potter J. Associations between family history of cancer and genes coding for metabolizing enzymes (United States). Cancer Causes Control 2000;11(9):799-803.
15. Brown NJ, Murphey LJ, Srikuma N, Koschachuhanan N, Williams GH, Vaughan DE. Interactive effect of PAI-1 4G/5G genotype and salt intake on PAI-1 antigen. Arterioscler Thromb Vasc Biol 2001;21(6):1071-1077.
16. Li H, Fan J. A general test of association for complex diseases with variable age of onset. Genet Epidemiol 2000;19(Suppl 1):S43-S49.
17. Siegmund KD, Langholz B, Kraft P, Thomas DC. Testing linkage disequilibrium in sibships. Am J Hum Genet 2000;67(1):244-248.
18. Deitcher SR, Crowe J. Association between the major genetic determinant of basal plasminogen activator inhibitor-1 (PAI-1) activity and breast cancer lymphatic invasion and axillary lymph node metastasis at diagnosis. In: Proceedings of the AACR 2004.
19. Goldgar DE, Easton DF, Cannon-Albright LA, Skolnick MH. Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands. J Natl Cancer Inst 1994; 86(21):1600-1608.
20. Schaid DJ. The complex genetic epidemiology of prostate cancer. Hum Mol Genet 2004;13(1):R103-R121.
21. Klein EA, Kupelian PA, Witte JS. Does a family history of prostate cancer result in more aggressive disease? Prostate Cancer Prostatic Dis 1998;1:297-300.